Poster #14-006 describes the first successful
treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous
CD19-targeted CAR-T cells
Kyverna to host a conference call on
April 16 to review recent
named-patient experience in patients suffering from multiple
sclerosis and myasthenia gravis
EMERYVILLE, Calif., April 11,
2024 /PRNewswire/ -- Kyverna Therapeutics, Inc.
(Nasdaq: KYTX), a patient-centered, clinical-stage
biopharmaceutical company focused on developing cell therapies for
patients suffering from autoimmune diseases, announced today its
attendance at the 2024 annual meeting of the American Academy of
Neurology to be held in Denver,
Colorado, starting on April
13.
Of particular interest:
- On April 15, Jeremias Motte, M.D., a senior physician and
neurologist at the University Hospital in Bochum, Germany, will present a case study of a
successful treatment of patients suffering from concomitant
myasthenia gravis and Lambert-Eaton syndrome1
- On April 16, Kyverna will host a
conference call discussing recent experience with KYV-101 in
patients suffering from neurological autoimmune diseases. Call-in
details will be published in advance on the company's website
(ir.kyvernatx.com)
- On April 16, Marinos Dalakas,
M.D., FAAN, a professor at the Thomas
Jefferson University Hospitals and a neurology specialist,
will discuss advances in the therapeutic algorithm for autoimmune
neuromuscular disorders
"We welcome the publication of these reports from named-patient
case studies that contribute to building confidence in the desired
safety and efficacy profile for innovating CAR T-cell therapies,"
said Jeffrey Dunn, M.D., the Lily
Sarafan director of Neuroimmunology and clinical professor and
chief of Neuroimmunology within the Department of Neurology and
Neurological Sciences at Stanford
University in Palo Alto,
California.
"We look forward to attending AAN and engaging with the
scientific community in seeking to develop paradigm-shifting
treatment options for patients living with autoimmune diseases,"
said Peter Maag, Ph.D., chief
executive officer of Kyverna.
Chimeric antigen receptor (CAR) T-cell therapy involves
modifying a patient's T cells to recognize and remove B cells in
the patient's body. CD19 CAR T-cell therapy specifically targets
CD19, a protein expressed on the surface of B cells, which are
involved in various types of autoimmune diseases.
About Multiple Sclerosis (MS)
Multiple sclerosis is a chronic neurodegenerative autoimmune
disease affecting over 2.8 million individuals
worldwide2. It affects more frequently women, people of
Northern European descent, and is also associated with certain
environmental and genetic factors. Patients with MS can experience
a range of symptoms including blurred vision, slurred speech,
tremors, numbness, extreme fatigue, problems with memory and
concentration, and, in severe cases, the inability to walk or
stand.
Current disease-modifying treatments for MS aim to reduce the
frequency of disease relapses and delay progression of disability,
but the disease remains a chronic condition that will progressively
worsen for most patients.
About Myasthenia Gravis (MG)
Myasthenia gravis is an autoimmune disorder associated with muscle
weakness in tissues throughout the body, potentially manifesting in
partial paralysis of eye movements, problems in chewing and
swallowing, respiratory problems, speech difficulties and weakness
in skeletal muscles. MG patients develop antibodies that lead to an
immunological attack on critical signaling proteins at the junction
between nerve and muscle cells, thereby inhibiting the ability of
nerves to communicate properly with muscles. The symptoms of the
disease can be transient and in the early stages of the disease can
remit spontaneously. However, as the disease progresses,
symptom-free periods become less frequent and disease exacerbations
can last for months. Disease symptoms reach their maximum levels
within two to three years in approximately 80% of patients. Up to
20% of MG patients experience respiratory crisis at least once in
their lives.3
About KYV-101
KYV-101 is an autologous, fully human CD19 CAR T-cell product
candidate for use in B cell-driven autoimmune diseases. The CAR in
KYV-101 was designed by the National Institutes of Health (NIH) to
improve tolerability and tested in a 20-patient Phase 1 trial in
oncology. Results were published by the NIH in Nature
Medicine4.
KYV-101 is currently being evaluated in sponsored,
open-label, Phase 1/2 trials of KYV-101 in patients with lupus
nephritis, an autoimmune disease in which more than half of
patients do not achieve a complete response to current therapies
and are at risk of developing kidney failure. Additionally, FDA's
IND clearance has been obtained for Phase 2 trials of KYV-101 for
multiple sclerosis and myasthenia gravis, and a Phase 1/2 trial for
systemic sclerosis.
We believe that the differentiated properties of KYV-101 are
critical for the potential success of CAR T cells as autoimmune
disease therapies.
KYV-101 is also being evaluated in investigator-initiated trials
for multiple indications in multiple geographies.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc.
(NASDAQ: KYTX) is a patient-centered, clinical-stage
biopharmaceutical company focused on developing cell therapies for
patients suffering from autoimmune diseases.
Our lead CAR T-cell therapy candidate, KYV-101 is advancing
through clinical development with sponsored clinical trials across
two broad areas of autoimmune disease: rheumatology and neurology,
including Phase 2 trials for multiple sclerosis and myasthenia
gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing
multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna's pipeline includes next-generation CAR T-cell therapies
in both autologous and allogeneic formats with properties intended
to be well suited for use in B cell-driven autoimmune diseases.
Forward-Looking Statements
Statements in this press
release about future expectations, plans and prospects, as well as
any other statements regarding matters that are not historical
facts, may constitute "forward-looking statements." The words,
without limitation, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. Forward-looking statements in
this press release include, without limitation, those related to:
the potential impact of named-patient case studies; Kyverna's goals
to develop certain paradigm-shifting treatment options; Kyverna's
beliefs about the differentiated properties of KYV-101; and
Kyverna's clinical trials. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, including: uncertainties related to
market conditions, and other factors discussed in the "Risk
Factors" section of Kyverna's most recent Annual Report on Form
10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or
may subsequently file with the U.S. Securities and Exchange
Commission. Any forward-looking statements contained in this press
release are based on the current expectations of Kyverna's
management team and speak only as of the date hereof, and Kyverna
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information, please
visit https://kyvernatx.com.
Kyverna Media Contact:
Consort Partners for
Kyverna
kyvernatx@consortpartners.com
# # #
1. Motte et al., 2024
AAN 2024 Annual Meeting. Poster #14-006.
https://www.aan.com/msa/Public/Events/AbstractDetails/55878
|
|
2. Walton et al,.
Mult Scler. 2020; 26:1816-1821.
|
|
3. Payus et al., Am
J Case Rep. 2021; 22: e928419-1–e928419-4
|
|
4. Brudno et al.,
Nature Medicine 2020; 26:270-280.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-to-attend-the-2024-american-academy-of-neurology-aan-annual-meeting-in-denver-co-with-data-on-kyv-101-in-the-treatment-of-patients-with-neurological-autoimmune-diseases-302114930.html
SOURCE Kyverna Therapeutics